The earnings call highlighted significant achievements, including record-setting revenue, improved gross margins, and strong growth in key segments. Despite slight delays in the divestiture process and marginal annual revenue growth, the overall financial and strategic progress positions the company well for future success.

Company Guidance -

Q1 2026

During ImmunoPrecise Antibodies' fourth quarter and full fiscal year 2025 earnings call, the company reported record-setting performance with $7 million in revenue for the fourth quarter, marking the highest quarterly revenue in its history. This was an 8.1% increase from the previous year and a 13.5% increase from the prior quarter. The gross margin improved significantly to 64% in Q4, up from 48% in the same quarter last year, contributing to a full-year gross margin of 55%, up from 49% in the previous fiscal year. This improvement was largely driven by the BioStrand segment, which experienced over 180% year-over-year growth, achieving gross margins near 90%. The company also reported a narrowed adjusted EBITDA loss of $316,000 for Q4, a substantial improvement from a $1.7 million loss in the year-ago period. Additionally, the Canadian business saw robust growth, with sales orders reaching $4.3 million in Q4, a 47% year-over-year increase. ImmunoPrecise Antibodies is in the final stages of divesting its Dutch subsidiary, which is expected to streamline operations and strengthen the balance sheet. The company plans to rebrand, emphasizing its transition to a bio-native AI platform with the LENSai platform at its core, aiming to enhance drug discovery processes and strengthen its competitive edge.

Record-Setting Fourth Quarter Revenue

ImmunoPrecise Antibodies (IPA) achieved its highest quarterly revenue in company history with $7 million, marking a significant milestone.

Significant Improvement in Gross Margins

Gross margin improved to 64% in Q4, up from 48% in the same quarter of the previous fiscal year. For the full fiscal year, gross margins expanded by 600 basis points from 49% to 55%.

BioStrand Segment Growth

BioStrand segment grew more than 180% year-over-year, delivering gross margins approaching 90%.

Reduction in Adjusted EBITDA Loss

Adjusted EBITDA loss was narrowed to $316,000 in the fourth quarter, a significant improvement from a loss of $1.7 million in the same quarter last year.

Strong Growth in Canadian Business

Canadian business showed strong growth with sales orders reaching $4.3 million in Q4, more than double historical quarters.

Compliance with NASDAQ Requirements

Regained compliance with NASDAQ's minimum bid price requirement, reflecting growing market confidence.

Strategic Collaborations and Partnerships

Entered into strategic collaborations with companies like RIBOPRO and a multibillion-dollar technology company, enhancing platform capabilities and expanding market reach.

Strong Cash Position

Held $10.8 million in cash as of April 30, 2025, compared to $3.5 million at fiscal year-end 2024, indicating financial discipline.

ImmunoPrecise Antibodies (IPA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IPA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Sep 11, 2025	2026 (Q1)	- / -	-0.109	―	―	―
Jul 29, 2025	2025 (Q4)	-0.04 / -0.04	-0.523	93.06% (+0.49)	―
Mar 28, 2025	2025 (Q3)	-0.06 / -0.48	-0.08	-500.00% (-0.40)	―
Dec 10, 2024	2025 (Q2)	-0.07 / -0.07	-0.073	10.00% (<+0.01)	―
Sep 16, 2024	2025 (Q1)	-0.08 / -0.11	-0.102	-7.14% (>-0.01)	―
Jul 29, 2024	2024 (Q4)	-0.08 / -0.52	-0.145	-260.00% (-0.38)	―
Mar 14, 2024	2024 (Q3)	-0.07 / -0.08	-0.138	42.11% (+0.06)	―
Dec 14, 2023	2024 (Q2)	-0.09 / -0.07	-0.218	66.67% (+0.15)	―
Sep 14, 2023	2024 (Q1)	-0.15 / -0.10	-0.276	63.16% (+0.17)	―
Jul 07, 2023	2023 (Q4)	-0.12 / -0.15	-0.174	16.67% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IPA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$2.02	$1.72	-14.85%
Mar 28, 2025	$0.44	$0.39	-11.36%
Dec 10, 2024	$0.42	$0.40	-4.76%
Sep 16, 2024	$0.67	$0.54	-19.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ImmunoPrecise Antibodies (IPA) report earnings?

ImmunoPrecise Antibodies (IPA) is schdueled to report earning on Sep 11, 2025, TBA (Confirmed).

What is ImmunoPrecise Antibodies (IPA) earnings time?

ImmunoPrecise Antibodies (IPA) earnings time is at Sep 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IPA EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing